Racial/Ethnic Disparities in Outcomes After Percutaneous Coronary Intervention. 2023

Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
Divisions of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California. Electronic address: drwang@mednet.ucla.edu.

Asian American/Pacific Islanders (AAPIs) and Hispanics are growing minority United States populations, but are poorly represented in the cardiovascular literature. This study examines guideline adherence and outcomes in AAPIs and Hispanics compared with non-Hispanic Whites (NHWs) in a quaternary care center after inpatient percutaneous coronary intervention (PCI). The primary end points were inpatient post-PCI bleed, heart failure, cardiogenic shock, and all-cause mortality, whereas the secondary end point was the prescription rate of post-PCI guideline-directed medical therapy including aspirin, statins, P2Y12 receptor blockers, and cardiopulmonary rehabilitation. Intergroup differences were assessed through analysis of variance or two-way chi-square tests, and the association of race with binary outcomes was examined through logistic regression with NHW as the reference group. Compared with NHW, AAPIs, and Hispanics had higher odds of diabetes mellitus, and AAPIs had higher odds of hypertension and being on dialysis. Hispanics had higher odds of post-PCI mortality versus NHW, both in acute coronary syndrome (odds ratio [OR] 2.04, p = 0.03) and elective PCI (OR 2.51, p = 0.04). AAPI also trended toward higher mortality than NHW in both categories. AAPIs were found to have higher odds of statin prescription (OR 1.91, p = 0.04). Hispanics had lower odds of ticagrelor prescription versus NHW (OR 0.65, p = 0.04), and AAPIs trended toward such. No differences were found for cardiopulmonary rehabilitation prescriptions in groups. This study suggests that despite quality improvement efforts, disparities remain in postprocedural outcomes in minority groups in comparison with NHW.

UI MeSH Term Description Entries
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094202 Asian American Native Hawaiian and Pacific Islander Members of Asian American, Native Hawaiian, and Pacific Islander community. AANHPI,Asian American Pacific Islander,Asian Americans Pacific Islanders
D012770 Shock, Cardiogenic Shock resulting from diminution of cardiac output in heart disease. Cardiogenic Shock
D054058 Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION. Acute Coronary Syndromes,Coronary Syndrome, Acute,Coronary Syndromes, Acute,Syndrome, Acute Coronary,Syndromes, Acute Coronary
D062645 Percutaneous Coronary Intervention A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting. Percutaneous Coronary Revascularization,Coronary Intervention, Percutaneous,Coronary Interventions, Percutaneous,Coronary Revascularization, Percutaneous,Coronary Revascularizations, Percutaneous,Intervention, Percutaneous Coronary,Interventions, Percutaneous Coronary,Percutaneous Coronary Interventions,Percutaneous Coronary Revascularizations,Revascularization, Percutaneous Coronary,Revascularizations, Percutaneous Coronary
D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. HMG-CoA Reductase Inhibitor,HMG-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitor,Statin,Statins, HMG-CoA,Inhibitors, HMG-CoA Reductase,Inhibitors, Hydroxymethylglutaryl-CoA,Inhibitors, Hydroxymethylglutaryl-Coenzyme A,Statins,HMG CoA Reductase Inhibitor,HMG CoA Reductase Inhibitors,HMG-CoA Statins,Hydroxymethylglutaryl CoA Reductase Inhibitor,Hydroxymethylglutaryl CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Inhibitors,Hydroxymethylglutaryl-Coenzyme A Inhibitors,Inhibitors, HMG CoA Reductase,Inhibitors, Hydroxymethylglutaryl CoA,Inhibitors, Hydroxymethylglutaryl Coenzyme A,Inhibitors, Hydroxymethylglutaryl-CoA Reductase,Reductase Inhibitor, Hydroxymethylglutaryl-CoA,Reductase Inhibitors, HMG-CoA,Reductase Inhibitors, Hydroxymethylglutaryl-CoA,Statins, HMG CoA

Related Publications

Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
March 2009, The American journal of cardiology,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
December 2019, Cardiovascular revascularization medicine : including molecular interventions,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
November 2023, The American journal of cardiology,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
April 2019, JAMA pediatrics,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
April 2019, JAMA pediatrics,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
January 2009, NeuroRehabilitation,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
June 2024, International journal of cardiology,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
April 2019, JAMA pediatrics,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
March 2023, Clinical pharmacology and therapeutics,
Daniel R Wang, and Joshua Li, and Rushi V Parikh, and Boback Ziaeian, and Olcay Aksoy, and Nicholas J Jackson, and Jeffrey J Hsu
February 2013, Journal of interventional cardiology,
Copied contents to your clipboard!